NASDAQ · GDRX
GoodRx Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GDRX: Nov 3, 2026
GoodRx Holdings, Inc. Class A Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.04. The reported EPS for the same quarter last year was $0.04.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.04 | $0.05 | $0.03 | 3 |
| Dec 2026 | $0.04 | $0.06 | $0.03 | 3 |
| Mar 2027 | $0.05 | $0.06 | $0.04 | 2 |
| Jun 2027 | $0.05 | $0.06 | $0.05 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · BNK Invest · MarketBeat- Zacks · Oct 27, 5:20 PM EDTIcon PLC (ICLR) Q3 Earnings and Revenues Beat EstimatesIcon PLC (ICLR) delivered earnings and revenue surprises of +0.76% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 21, 11:03 AM EDTHIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.
- The Motley Fool · Aug 12, 7:03 PM EDTGoodRx (GDRX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- BNK Invest · Aug 12, 9:38 AM EDTGoodRx Holdings Reaches Analyst Target PriceIn recent trading, shares of GoodRx Holdings Inc (Symbol: GDRX) have crossed above the average analyst 12-month target price of $3.73, changing hands for $3.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on va
- MarketBeat · Aug 6, 2:04 PM EDTGoodRx Q2 Earnings Call HighlightsWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?GoodRx (NASDAQ:GDRX) reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses of
- RTTNews · Aug 5, 11:06 PM EDTGoodRx Holdings, Inc. Q2 Profit Falls(RTTNews) – GoodRx Holdings, Inc. (GDRX) announced earnings for second quarter that Drops, from last year
- Zacks · Aug 5, 8:35 PM EDTGoodRx Holdings, Inc. (GDRX) Q2 Earnings Match EstimatesGoodRx (GDRX) delivered earnings and revenue surprises of 0.00% and +3.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 8:30 PM EDTGoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Aug 4, 7:00 PM EDTArdent Health, Inc. (ARDT) Q2 Earnings Lag EstimatesArdent Health, Inc. (ARDT) delivered earnings and revenue surprises of -29.41% and +1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 24, 7:24 AM EDTStrength Seen in Labcorp (LH): Can Its 3.4% Jump Turn into More Strength?Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Zacks · Jul 8, 12:00 PM EDTGoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jul 8, 11:40 AM EDTGDRX or HQY: Which Is the Better Value Stock Right Now?GDRX vs. HQY: Which Stock Is the Better Value Option?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for GoodRx Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.